Duloxetine
Product Images NDC 62034-021

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 62034-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg 10x10ud 100ct (62034 021 77)

60mg 10x10ud 100ct (62034 021 77)
This is a description of Duloxetine delayed-release capsules in the strength of 60 mg. Each capsule contains 67.3 mg of Duloxetine hydrochloride USP which is equivalent to 60 mg of Duloxetine. The package includes a patient-dispensation guide, and the medication should be kept away from children. The dosage is to be followed as per the package insert. The packaging is not child-resistant, and thus, a child-resistant container should be utilized. The drug product is manufactured by Breckenridge Pharmaceutical Inc. and marketed by Blenheim Pharmacal Inc., with NDC 62034-021-77. It is advisable to store the medicine at a temperature of 25°C (77°F) and can be kept between 15" to 30°C (58" to 86°F).*
FDA Label Image

30mg 10x10ud 100ct (62034 029 77)

30mg 10x10ud 100ct (62034 029 77)
This is a medication information for delayed-release capsules of Duloxetine. It is important to keep the medication away from children and is dispensed for outpatient use. Each capsule contains 33.7 mg of duloxetine. The storage temperature of the drug is between 15 to 30°C. A guide is provided separately to each patient. The drug is marketed by Blénheim Phamacal, Inc.*
FDA Label Image

Structure (Duloxetine 01)

Structure (Duloxetine 01)
FDA Label Image

Figure 1 (Duloxetine 02)

Figure 1 (Duloxetine 02)
FDA Label Image

Figure 2 (Duloxetine 03)

Figure 2 (Duloxetine 03)
FDA Label Image

Figure 3 (Duloxetine 04)

Figure 3 (Duloxetine 04)
The text describes a graph showing the percentage of patients who improved while taking a medication (CYM80/120 mg once daily) compared to a placebo. The graph also shows the percentage of improvement in pain from baseline (BOCF).*
FDA Label Image

Figure 4 (Duloxetine 05)

Figure 4 (Duloxetine 05)
This is a chart showing the percentage of patient improvement in pain from baseline (BOCF) with two different treatments: placebo and CYM60 mg once daily. The percentage of improvement ranges from 0-100%, with the CYM60 mg treatment showing a higher percentage of improvement than the placebo.*
FDA Label Image

Figure 5 (Duloxetine 06)

Figure 5 (Duloxetine 06)
This is a graph representing the percentage of patients who improved after being treated with a placebo versus CYM60/120 mg once daily. The graph also displays the percentage of improvement in pain from baseline. No further information is available as this is an excerpt from a larger document.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.